Skip to Content

Reslizumab Pregnancy and Breastfeeding Warnings

Reslizumab is also known as: Cinqair

Medically reviewed on April 25, 2018

Reslizumab Pregnancy Warnings

In animal studies this drug was not teratogenic and did not have any effects on fetal development up to 4 months of age. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

This drug should be used during pregnancy only if the benefit outweighs the risk.

US FDA pregnancy category: Not assigned

Risk Summary: Monoclonal antibodies, such as this drug, are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy.

Comment:
-In women with poorly or moderately controlled asthma, there is an increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control.

See references

Reslizumab Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Unknown; however, human IgG is present
Excreted into animal milk: Yes

Comment: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Cinqair (reslizumab)." Teva Pharmaceuticals USA, North Wales, PA.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Cinqair (reslizumab)." Teva Pharmaceuticals USA, North Wales, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide